TRDA Long Call Strategy

TRDA (Entrada Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

TRDA (Entrada Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $300.5M, a beta of -0.26 versus the broader market, a 52-week range of 4.93-16.45, average daily share volume of 369K, a public-listing history dating back to 2021, approximately 183 full-time employees. These structural characteristics shape how TRDA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.26 indicates TRDA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on TRDA?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current TRDA snapshot

As of June 30, 2026, spot at $7.38, ATM IV 117.50%, IV rank 21.14%, expected move 33.69%. The long call on TRDA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long call structure on TRDA specifically: TRDA IV at 117.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a TRDA long call, with a market-implied 1-standard-deviation move of approximately 33.69% (roughly $2.49 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TRDA expiries trade a higher absolute premium for lower per-day decay. Position sizing on TRDA should anchor to the underlying notional of $7.38 per share and to the trader's directional view on TRDA stock.

TRDA long call setup

The TRDA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TRDA near $7.38, the first option leg uses a $7.38 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TRDA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TRDA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$7.38N/A

TRDA long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

TRDA long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on TRDA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on TRDA

Long calls on TRDA express a bullish thesis with defined risk; traders use them ahead of TRDA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

TRDA thesis for this long call

The market-implied 1-standard-deviation range for TRDA extends from approximately $4.89 on the downside to $9.87 on the upside. A TRDA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current TRDA IV rank near 21.14% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TRDA at 117.50%. As a Healthcare name, TRDA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TRDA-specific events.

TRDA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TRDA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TRDA alongside the broader basket even when TRDA-specific fundamentals are unchanged. Long-premium structures like a long call on TRDA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current TRDA chain quotes before placing a trade.

Frequently asked questions

What is a long call on TRDA?
A long call on TRDA is the long call strategy applied to TRDA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With TRDA stock trading near $7.38, the strikes shown on this page are snapped to the nearest listed TRDA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TRDA long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the TRDA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 117.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TRDA long call?
The breakeven for the TRDA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TRDA market-implied 1-standard-deviation expected move is approximately 33.69%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on TRDA?
Long calls on TRDA express a bullish thesis with defined risk; traders use them ahead of TRDA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current TRDA implied volatility affect this long call?
TRDA ATM IV is at 117.50% with IV rank near 21.14%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related TRDA analysis